Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Xenova Group plc (XEN)

  Print      Mail a friend

Monday 14 June, 2004

Xenova Group plc

Xenova Group plc - Research Update

Positive Results from TA-CD Cocaine Vaccine Trial Presented at CPDD

Slough, UK, 14 June 2004 - Xenova Group plc (London Stock Exchange:
XEN; NASDAQ: XNVA) announced today the presentation of results of two
dose escalation Phase II studies of TA-CD, a vaccine being developed
for the treatment of cocaine addiction, at the College on Problems of
Drug Dependence 66th Annual Scientific Meeting in Puerto Rico, June
12-17.  Presented by Dr Bridget Martell, the trials were carried out
by Professor Thomas Kosten and his team at Yale University School of

The two open-labelled, dose-escalation studies carried out on an
out-patient basis, evaluated safety, immunogenicity and clinical
efficacy of TA-CD in a total of 22 cocaine users.  One of the two
studies comprised nine cocaine dependent subjects receiving the TA-CD
vaccine and assessed for relapse prevention; these subjects were
required to have been free of cocaine use for the two weeks prior to
entering the study.  The second study included 13 cocaine dependent
subjects for abstinence initiation, who were not required to have
negative urine cocaine tests prior to enrolment.

Subjects received between three 100 mcg doses and five 400 mcg doses
of the TA-CD vaccine (up to 2000 mcg in total).  TA-CD was well
tolerated in the 20 subjects who completed the two studies.

Results from both studies showed that the maximum mean antibody
response occurred between 70 and 90 days post vaccination with
specific cocaine antibodies persisting for at least six months.
Eight subjects also received a booster 15-18 months post vaccination
with TA-CD, all of whom showed increased levels of antibodies two to
four weeks later.

Three quarters (75%) of the relapse prevention study group maintained
abstinence from cocaine use during the 12-week study duration with
100% relapsing after 12 months when antibody levels had dropped.

In the abstinence initiation study group, 58% achieved and maintained
abstinence during the 12-week study and 42% continued to be cocaine
free after six months.

The authors additionally reported that the likelihood of using
cocaine decreased in those subjects who received a more intense
vaccination schedule and as a result were observed to produce higher
levels of anti-cocaine antibodies.  88% of subjects in one study and
63% of subjects in the other, who relapsed within six months,
reported a reduction in the euphoric effects of cocaine.

Bridget Martell, MD, MA, Associate Research Scientist at Yale
University and involved in the TA-CD trials said, "Cocaine dependent
users have a serious need for assistance with achieving and
maintaining abstinence.  We are impressed with these results which,
although on a comparatively small number of subjects, are
particularly significant as a number of addicts receiving the TA-CD
vaccine were able to remain abstinent during the study periods."

David Oxlade, Chief Executive Officer of Xenova said, "These very
encouraging results give a strong indication of proof of concept for
the TA-CD cocaine vaccine and further validate its potential in
assisting cocaine addicts to achieve abstinence."

This study was supported by the US National Institute of Drug Abuse
(NIDA).  NIDA has also supported earlier clinical work on TA-CD.
NIDA has no rights to the commercialisation of TA-CD nor is funding
required to be repaid by Xenova.


Xenova Group plc                          +44 (0)1753 706600
David A. Oxlade, Chief Executive Officer
Daniel Abrams, Finance Director
Veronica Cefis Sellar, Headof CorporateCommunications

UK- Financial Dynamics                 +44 (0)20 7831 3113
David Yates
Ben Atwell

US- Trout Group/BMC Communications
             +1 212 477 9007
Media:              Brad Miles
Investors:        Lee Stern

Xenova Group plc is a UK-based biopharmaceutical company focused on
the development of novel drugs to treat cancer and addiction with a
secondary focus in immunotherapy.  The Company has a broad pipeline
of products in clinical development, including three cancer
programmes:  its lead product TransMIDTM, for the treatment of
high-grade glioma, is in Phase III trials, and its novel DNA
targeting agents and XR303 are both in Phase I for cancer
indications.  Xenova is also developing two therapeutic vaccines for
cocaine and nicotine addiction, which are in Phase II and Phase I
trials respectively.  Quoted on the London Stock Exchange (XEN) and
on NASDAQ (XNVA), Xenova employs approximately 112 people throughout
its sites in the UK and North America. (Reuters XEN.L; Bloomberg XEN
For further information about Xenova and its products please visit
the Xenova website at

Notes to Editors

Cocaine Prevalence

The Office of National Statistics estimate that there are currently
475,000 powder cocaine and 200,000 crack cocaine addicts in Britain.
UK Government figures indicate that deaths caused by Class A drugs
rose from 96 in 2001 to 139 in 2002 and that deaths from cocaine
poisoning have more than doubled with medical evidence that cocaine
causes the heart to age prematurely and leads to the rupture of blood
vessels.  According to Home Office figures, more than 3 million
people in the UK spend a total of £6.6 billion on illegal drugs per

In the US, it is estimated that there are approximately 1.7 million
addicts, some 3 million occasional users and about 900,000 cocaine
users seek medical help for their cocaine addiction every year (Lewin
Group report from 1997 based on data from SAMHSA Substance Abuse
Mental Health Services Administration).

The US Department of Health and Human Services 2002 National Survey
on Drug Use found that more than 33 million people age 12 and older
had used cocaine at least once in their lifetime. According to What
America's Users Spend in Illegal Drugs, users spent $35.3 billion on
cocaine in 2000, consuming 259 metric tons of cocaine


a d v e r t i s e m e n t